NASH: the tribulations of conducting NASH trials.
Designing clinical trials for the treatment of NASH is challenging. The pathogenesis of this disease is poorly understood and is probably multifactorial. A trial of a phosphodiesterase-4 inhibitor produced negative results, despite promising preclinical data. Examining why this trial failed might help us design better trials of treatments for NASH in the future.
Saint Louis University, 3635 Vista Ave, Saint Louis, MO 63105, USA.
Brent A
BA
Neuschwander-Tetri
D005260:Female; D006801:Humans; D008297:Male; D065626:Non-alcoholic Fatty Liver Disease / Q000188:drug therapy*; D058988:Phosphodiesterase 4 Inhibitors / Q000008:administration & dosage*
D058988:Phosphodiesterase 4 Inhibitors